Even with this increase, the company currently only uses 27% of its cash flows to fund its 1.1% dividend yield. This leaves plenty of additional funding available for future increases, making ASML a ...

Story by Josh Kohn-Lindquist • 6d N ot only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader ...